Nasdaq
$18.05▲ 0.28%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $21.02BShares out 11.600M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
11- 10.8After-hours26.10.09 05:45SC TO-COther#●●●#●●●
Viatris Inc
Viatris Inc. announced an agreement on October 8, 2026, to acquire Pacira BioSciences. Viatris plans to commence a tender offer through its subsidiary to purchase all outstanding shares of Pacira, followed by a merger.…more
$18.05+0.28%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.8Pre-market26.10.08 21:45SC TO-COther
Viatris Inc
Viatris has entered into a definitive agreement to acquire Pacira BioSciences for $36.50 per share in cash, representing an aggregate equity value of $1.65 billion. The transaction, aimed at strengthening Viatris' non-opioid pain therapy portfolio, is expected to close by the end of 2026. Upon completion, Pacira will become a wholly owned subsidiary of Viatris and its common stock will be delisted from the Nasdaq.…more
$18.05+0.28%vs prev closeView filingShare - 10.8Pre-market26.10.08 21:388-KKey event
Viatris Inc
Viatris Inc. has entered into a definitive agreement to acquire Pacira BioSciences for $36.50 per share in cash, representing an aggregate equity value of approximately $1.65 billion. This acquisition aims to strengthen Viatris' innovative medicines portfolio in non-opioid pain therapies and is expected to close by the end of 2026. Upon completion, Pacira will become a wholly owned subsidiary of Viatris and will be delisted from the Nasdaq.…more
$18.05+0.28%vs prev closeView filingShare
10 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.16After-hours26.10.17 05:05#●●●#●●●
Viatris Receives FDA Approval For RYZUMVI To Treat Presbyopia
Viatris announced that the FDA has approved its RYZUMVI ophthalmic solution for the treatment of adult presbyopia. The company is currently seeking a U.S. partner to commercialize the product for this new indication.…more
$18.05+0.28%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.8Regular26.10.09 01:49
●●●●●●●● ●●●●● ●●●●●●
Viatris has agreed to acquire Pacira BioSciences for $1.65 billion to strengthen its non-opioid pain management portfolio. The deal is expected to contribute positively to Viatris' financial metrics and expand its innovative medicines business.…more
$18.05+0.28%vs prev closeShareBenzinga - 10.8Pre-market26.10.08 20:47
●●●●●●●● ●●●●● ●●●●●●
Viatris announced a definitive agreement to acquire Pacira BioSciences in an all-cash deal valued at $1.65 billion, or $36.50 per share. The transaction is expected to close by the end of 2026.…more
$18.05+0.28%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report